IMPROVED HEMOSTATICS FOR TRAUMATIC HYPHEMA

出血进入眼前房或玻璃体房可能是由于 钝性创伤或玻璃体切除的并发症。外伤性前房积血 前房出血通常由钝挫伤引起。 充血可导致角膜血染、继发性青光眼、慢性 开角型青光眼，或视网膜中央动脉阻塞。止血药 纤溶酶原激活抑制物-氨基己酸(EACA) 每天30克的剂量已被证明在临床上是有效的 外伤性前房积血的处理。这样做的副作用和高昂的成本 大剂量的药物限制了其作为一般预防措施的使用。 防止眼部钝挫伤和眼球损伤后继发出血 玻璃体切除手术。该项目将涉及类似物的设计和合成 EACA和相关止血药的药物，预计将产生抑制剂 这将与纤溶酶原更紧密地结合几个数量级。是这样的 药物将允许使用低得多的剂量，从而降低成本 治疗效果好，副作用少。

Bleeding into the anterior or vitreal chambers of the eye may result from blunt trauma or as a complication of vitrectomy. Traumatic hyphema is hemorrhage into the anterior chamber often resulting from blunt trauma. Hyphemas may lead to corneal blood staining, secondary glaucoma, chronic open angle glaucoma, or central retinal artery occlusion. The hemostatic inhibitor of plasminogen activation epsilon-aminocaproic acid (EACA) at doses of up to 30 g/day has been demonstrated to be effective in clinical management of traumatic hyphema. The side effects and high cost of such large doses of the drug have limited its use as a general prophylaxis against secondary hemorrhage in cases of blunt trauma to the eye and in vitrectomy. This project will involve the design and synthesis of analogs of EACA and related hemostatics, and is expected to produce inhibitors which will bind orders of magnitude more tightly to plasminogen. Such drugs would allow the use of much lower doses leading to reduced cost of treatment and fewer side effects.